Developments in the Management of Metastatic HER2-Positive Breast Cancer and Delivery of Patient-Centered Oncology Care
Developments in the Management of Metastatic HER2-Positive Breast Cancer and Delivery of Patient-Centered Oncology Care is organized by Physicians' Education Resource, LLC (PER).
Activity Overview:
HER2 expression is a marker of more aggressive disease and presents in about 25% of breast cancers. The treatment of HER2-positive breast cancer has evolved with the increasing availability of HER2-targeted therapies. The appropriate sequencing of therapies for patients with HER2-positive breast cancer can be complex, and pharmacists are integral to ensuring care coordination and providing medication expertise to the multidisciplinary care team. In this program, expert faculty will review recent clinical trial data and guideline recommendations detailing the use of HER2-targeted therapy for first-line treatment. Patient adherence to therapy remains a priority compounded by the cost of treatment and concerns of adverse effects of therapy. To ensure optimal patient outcomes, pharmacists must be prepared to make early interventions and assist the oncology care team with the identification and management of potential treatment-related adverse effects of HER2-targeted therapies. Oncology pharmacists are positioned to use information gained through this activity to provide education to patients and members of the health care team, monitor drug toxicities, and recommend dose adjustments as appropriate.
Learning Objectives:
At the completion of this activity, participants will be able to:
• Compare the mechanisms of action and administration of HER2-targeted therapies
• Interpret recent literature evaluating therapies in HER2-positive metastatic breast cancer and subsequent implications for changes in practice paradigms
• Identify adverse effect profiles and management strategies in efforts to improve adherence to and patient outcomes associated with HER2-targeted therapy
Additional details will be posted as soon as information is available.